佛波醇12,13-二己酸酯 | 37558-17-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 佛波醇12,13-二己酸酯
• 英文名称: Phorbol-12,13-dihexanoate
• 英文别名: [(1S,2S,6R,10S,11R,13S,14R,15R)-13-hexanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] hexanoate
• CAS: 37558-17-1
• 化学式: C₃₂H₄₈O₈
• 分子量: 560.7
• InChiKey: XGPRSRGBAHBMAF-NQWCLMGHSA-N

物化性质

• 沸点：
  546.15°C (rough estimate)
• 密度：
  1.1006 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Compositions and methods of use of phorbolesters
  申请人：Biosuccess Biotech Company

  公开号：EP2368555A1

  公开（公告）日：2011-09-28

  Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Thl cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseasesl. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.

  本发明提供了含有植物醇酯或植物醇酯衍生物的方法和组合物，用于治疗细胞病理疾病。细胞病理疾病可由多种途径引起，如艾滋病毒和艾滋病等病毒感染，或哺乳动物体内肿瘤的发展。本发明的方法和组合物对于抑制新的 HIV 感染、上调潜伏前病毒的病毒表达、抑制 HIV 诱导的细胞病理效应、下调 HIV 受体、增加 Thl 细胞因子表达、减少 Th2 细胞因子表达、增加 ERK 磷酸化、诱导恶性细胞凋亡、诱导缓解、维持缓解、作为化疗药物以及减少细胞病理疾病症状和可能伴随此类疾病的机会性感染l 均有效。本研究还提供了其他组合物和方法，这些组合物和方法采用了一种抗坏血酸酯或衍生物化合物与至少一种额外的制剂结合使用，如HAART方案中使用的制剂、用于治疗HIV引起的机会性感染的治疗制剂或化疗制剂，以产生针对哺乳动物体内细胞病理疾病的更有效的治疗工具。
• METHOD FOR INDUCING MYOCARDIAL DIFFERENTIATION OF PLURIPOTENT STEM CELLS USING LOW-MOLECULAR COMPOUND
  申请人：Kyoto University

  公开号：EP3150705A1

  公开（公告）日：2017-04-05

  The present invention provides a method for inducing cardiac differentiation of a pluripotent stem cell, which comprises the steps of (1) culturing a pluripotent stem cell in a medium containing a WNT signaling activator and a PCK activator and (2) culturing the cell after the step (1) in a medium containing a WNT signaling inhibitor, a Src inhibitor, and an EGFR inhibitor.

  本发明提供了一种诱导多能干细胞心脏分化的方法，该方法包括以下步骤：（1）在含有WNT信号激活剂和PCK激活剂的培养基中培养多能干细胞；（2）在步骤（1）之后，在含有WNT信号抑制剂、Src抑制剂和表皮生长因子受体抑制剂的培养基中培养细胞。
• FREEZING METHOD FOR AGGREGATES OF PLURIPOTENT STEM CELL-DERIVED MYOCARDIAL CELLS
  申请人：Kyoto University

  公开号：EP3431584A1

  公开（公告）日：2019-01-23

  The disclosure provides a method of freezing an aggregate of pluripotent stem cell-derived cardiomyocytes, comprising: (i) immersing an aggregate of pluripotent stem cell-derived cardiomyocytes in a cryoprotective solution; and (ii) freezing the aggregate immersed in the cryoprotective solution. The disclosure also provides a frozen aggregate of pluripotent stem cell-derived cardiomyocytes frozen by the method.

  本公开提供了一种冷冻多能干细胞衍生的心肌细胞集合体的方法，包括 (i) 将多能干细胞衍生的心肌细胞聚集体浸入低温保护溶液中；以及 (ii) 冻结浸泡在低温保护溶液中的聚集体。 本公开还提供了通过该方法冷冻的多能干细胞衍生的心肌细胞的冷冻集合体。
• IMMUNOMODULATOR
  申请人：National University Corporation Nara Institute of Science and Technology

  公开号：EP3501519A1

  公开（公告）日：2019-06-26

  The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.

  本发明提供了一种用于治疗或预防过敏性疾病的药物组合物。更具体地说，本发明提供了一种用于治疗或预防过敏性疾病的药物组合物，其中含有一种能诱导 B 细胞选择性 IgA 类转换的物质。作为诱导 B 细胞选择性 IgA 类转换的物质，可以使用 PKC 激活剂。此外，含有诱导 B 细胞选择性 IgA 类转换物质的组合物还可用作粘膜佐剂。
• PRODUCTION METHOD FOR PARASYMPATHETIC NERVE CELLS
  申请人：National Institute of Advanced Industrial Science and Technology

  公开号：EP3825397A1

  公开（公告）日：2021-05-26

  The present invention provides a method for producing parasympathetic neurons from neural crest cells or autonomic neural progenitor cells derived therefrom, comprising a step of culturing the neural crest cells or autonomic neural progenitor cells derived therefrom in the presence of a cAMP production promoter, a BDNF signaling pathway activator, a GDNF signaling pathway activator, an NGF signaling pathway activator, an NT-3 signaling pathway activator, vitamin C, a protein kinase C activator, and a retinoic acid receptor agonist.

  本发明提供了一种从神经嵴细胞或由其衍生的自主神经祖细胞产生副交感神经元的方法，包括在cAMP产生启动子存在下培养神经嵴细胞或由其衍生的自主神经祖细胞的步骤、BDNF信号通路激活剂、GDNF信号通路激活剂、NGF信号通路激活剂、NT-3信号通路激活剂、维生素C、蛋白激酶C激活剂和维甲酸受体激动剂。